{
    "clinical_study": {
        "@rank": "105776", 
        "arm_group": {
            "arm_group_label": "SAR302503", 
            "arm_group_type": "Experimental", 
            "description": "single treatment with oral dose up to 300 mg of SAR302503"
        }, 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      To study the effect of mild and moderate hepatic impairment on the pharmacokinetics of\n      SAR302503.\n\n      Secondary Objective:\n\n      To assess the tolerability of SAR302503 given as a single dose up to 300 mg in subjects with\n      mild and moderate and hepatic impairment and in matched subjects with normal hepatic\n      function."
        }, 
        "brief_title": "Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hepatic Impairment", 
        "condition_browse": {
            "mesh_term": "Liver Diseases"
        }, 
        "detailed_description": {
            "textblock": "Study duration=17-35 days"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n          -  Male or female subjects, between 18 and 75 years of age, inclusive.\n\n          -  Body weight between 50.0 and 115.0 kg, inclusive if male, and between 40.0 and 100.0\n             kg, inclusive if female, body mass index between 18.0 and 34.9 kg/m2, inclusive.\n\n          -  Stable chronic liver disease with Child-Pugh classification score between 5 and 9\n             assessed by medical history, physical examination, laboratory values\n\n          -  12-lead ECG without clinically significant abnormality\n\n          -  Laboratory parameters within the acceptable range for subjects with hepatic\n             impairment\n\n          -  Using a double contraception method\n\n        Exclusion criteria:\n\n          -  Uncontrolled clinically relevant cardiovascular, pulmonary, gastrointestinal,\n             metabolic, hematological, neurological, psychiatric, systemic, ocular, gynecologic\n             (if female), or infectious disease, or signs of acute illness.\n\n          -  Hepatocarcinoma.\n\n          -  Acute hepatitis\n\n          -  Any significant change in chronic treatment medication within 14 days before\n             inclusion\n\n          -  Concomitant treatment with or use of drugs or herbal agents known to be at least\n             moderate inhibitors or inducers CYP3A4 sensitive or narrow therapeutic index\n             substrate of CYP3A4\n\n          -  Concomitant treatment gastric pH modifying agent\n\n          -  Positive result on any of the following tests: anti-human immunodeficiency virus 1\n             and 2 antibodies (anti-HIV1 and anti HIV2 Ab).\n\n          -  Positive result on urine drug screen\n\n          -  Positive alcohol test.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "17", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01762462", 
            "org_study_id": "POP13450", 
            "secondary_id": "U1111-1118-5554"
        }, 
        "intervention": {
            "arm_group_label": "SAR302503", 
            "description": "Pharmaceutical form:capsule\nRoute of administration: oral", 
            "intervention_name": "SAR302503", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "August 28, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33014"
                    }, 
                    "name": "Investigational Site Number 840003"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32809"
                    }, 
                    "name": "Investigational Site Number 840002"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37920"
                    }, 
                    "name": "Investigational Site Number 840001"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Pharmacokinetic and Tolerability Study of SAR302503 Given as a Single 300 mg Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Pharmacokinetic parameter: Cmax, AUClast and AUC", 
            "safety_issue": "No", 
            "time_frame": "12 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01762462"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetic parameters : unbound AUC, unbound Cmax, CL/F, Vss/F , t1/2z, t1/2eff, Rac, pred", 
                "safety_issue": "No", 
                "time_frame": "12 days"
            }, 
            {
                "measure": "Safety parameters including Clinical tests", 
                "safety_issue": "Yes", 
                "time_frame": "16 days"
            }, 
            {
                "measure": "Safety parameters including laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "16 days"
            }, 
            {
                "measure": "Safety parameters including ECG parameters", 
                "safety_issue": "Yes", 
                "time_frame": "16 days"
            }, 
            {
                "measure": "Number of subjects with adverse events (AEs) - Time Frame:", 
                "safety_issue": "Yes", 
                "time_frame": "16 days"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}